Pradeyrol Développement

Investment Director Alexandre Le Vert runs day-to-day allocation and deal execution on behalf of founder Dr. Christian Pradeyrol. Le Vert also functions as CEO of two key portfolio companies, Imaxio and Osivax, giving the office an unusual operator-led decision framework. This means investment committee deliberations draw from active management experience inside the portfolio, not solely external advisory input.

The office maintains a strategic co-investment relationship with Institut Pasteur, one of Europe's premier biomedical research institutions. This partnership provides early visibility into vaccine and immunotherapy spinouts emerging from Institut Pasteur laboratories. Alexandre Le Vert's operational role at Imaxio and Osivax deepens the technical due-diligence capability and strengthens origination networks across European life sciences clusters.

The firm is a single-family office managing Dr. Christian Pradeyrol's private wealth. However, its investment posture — direct co-investments, SPV structures, and a concentrated operator-investor model where the Investment Director runs portfolio companies — resembles a sector-specialist venture firm more than a traditional diversified family office. No external limited partners are reported.

The office pursues a hybrid approach: primarily direct co-investments and special-purpose vehicles, supplemented by commitments to external venture capital and growth equity funds. Public records document both fund-of-funds activity and direct equity stakes, though the balance skews toward direct engagement where Alexandre Le Vert can bring operational involvement to bear.

The firm concentrates on healthcare services, digital health, energy transition, and climate technology. Within healthcare, vaccines and immunotherapy represent the deepest concentration, with Imaxio and Osivax as anchor holdings. The energy transition and climate allocations provide counter-cyclical diversification and align with European regulatory tailwinds.

Institut Pasteur serves as a strategic co-investment partner, collaborating on biotech ventures that emerge from its research pipeline. This is an institutional partnership, not a formal ownership link — Pasteur co-invests alongside the family office in select spinouts, and the relationship provides scientific validation and deal flow access that generic family offices cannot replicate.

The wealth originates from Dr. Christian Pradeyrol's career as a medical doctor and healthcare entrepreneur. He founded and built CHP Group, a private clinic group operating across France, before establishing the family office to manage the proceeds and redeploy capital into adjacent healthcare innovation sectors.